You are too kind!

Oh yes! 😂😂

One of the greatest shows on TV ever. I was particularly amused by the interpretation of the carrot and stick approach. 😂

Would be fascinating to do an SR+MA on AF as co-meds in trials vs IMP in trials? 🤔

For sure there is no dose response really for Pirfenidone some dose response for nintedanib but really good point!

No, in London.

However, another study highlighting the disappearing treatment effect! Check the placebo vs Pirfenidone groups! 😳😳 we really need better drugs to #CureIPF

There is a section on Familial Pulmonary Fibrosis, genetics & telomere length, a para on spatial transcriptomics & single cell analysis, also biomarkers. But they haven’t been used add granularity 2 classification. Whilst understandable this will eventually happen, so y rush 2 reclassify now?

Well if anybody can tell me what major paradigm shifting advance in diagnosis or pathogenesis which has substantially altered our understanding of Interstitial Lung Diseases has been included in this document I might change my mind.

I think it is as valuable and interesting as this 🤣🤣🤣

Turns out the average time from guideline to implementation is 17 years!!! (So I heard from an expert in that area!)

Not if the primary purpose is to promote the journal and the authors! #JustSaying #JobDone